Drug Research
US FDA approves Mylan Valsartan and Hydrochlorothiazide tablets
Mylan Pharmaceuticals, a subsidiary of Mylan, has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Valsartan and Hydrochlorothiazide Tablets USP. The product is...
Drug Research
Transgenomic to advance pancreatic cancer research with NIH grant
Transgenomic, a global biotechnology company, has won $100,000 small business technology transfer programme (STTR) Phase I grant from National Institutes of Health's (NIH) National Center for pancreatic cancer research. The project aims at developing...
Drug Research
US FDA approves Wockhardt hypertension drug
Wockhardt has received final approval from the US Food and Drug Administration ((FDA) to market extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used to treat hypertension. Felodipine is the generic name...
Drug Research
RayBiotech screening assays used to identify chemoresistance pathway
RayBiotech-developed antibody-based biomarker screening assays have been used to identify a critical pathway involved in chemotherapeutic resistance acquired by melanoma cancer cells. RayBiotech president and chief operating officer Rani Huang said the findings of...
Drug Research
Elsevier integrates Reaxys with electronic laboratory notebook
PerkinElmer has integrated its electronic laboratory notebook (ELN) with Elsevier's Reaxys, a web-based workflow solution designed for chemistry researchers in drug discovery, chemicals and academic research. PerkinElmer Informatics general manager Michael Stapleton said as...
Drug Research
Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China
Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC). Under the agreement, Ascletis gained an...
Drug Research
Takeda signs Omontys injection supply contract with Fresenius
Takeda Pharmaceuticals America (TPA) has signed a contract to supply Omontys injection to Fresenius Medical Care North America and certain of its affiliates. Omontys (peginesatide) injection is a synthetic, pegylated, peptide-based erythropoiesis-stimulating agent (ESA)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
